Oral News and Research

RSS

Cinryze data on hereditary angioedema presented at EAACI 2011

ViroPharma Incorporated today announced that data relating to Cinryze from nine accepted abstracts were presented as poster presentations at the 30th Congress of the European Academy of Allergy and Clinical Immunology (EAACI), June 11 through 15, in Istanbul, Turkey.

14 Jun 2011

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor.

14 Jun 2011

Cypress receives FDA approval for ZUTRIPRO, REZIRA NDA to treat cough and common cold

Cypress Pharmaceutical announced today that the Food and Drug Administration (FDA) approved a new drug application (NDA) for ZUTRIPRO Oral Solution (CIII) and REZIRA Oral Solution.

14 Jun 2011

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.

13 Jun 2011

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced an exclusive worldwide licensing agreement that will add two distinct nucleotide analogues to Vertex's hepatitis C portfolio.

13 Jun 2011

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two ongoing Phase I studies with MLN9708, the first oral proteasome inhibitor being studied in patients with relapsed and/or refractory multiple myeloma.

13 Jun 2011

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc., announced today that data on ADCETRIS (brentuximab vedotin) in relapsed or refractory Hodgkin lymphoma patients were featured in an oral presentation at the 16th Congress of the European Hematology Association (EHA) in London.

13 Jun 2011

Merck receives FDA approval for redesigned drug container labels

The U.S. Food and Drug Administration today is announcing the approval of Merck's redesigned drug container labels that include a new standardized format to improve readability and provide better information on product and strength differentiation.

13 Jun 2011

First Edition: June 10, 2011

Today's health policy headlines include reports about health law funding and policy particulars, as well as Dems' push to protect Medicaid.

10 Jun 2011

Battle over health law moves to Atlanta courtroom as judges weigh limits of the measure's powers

In perhaps the weightiest of the dozens of challenges to the Obama health care law, a panel of appellate judges grappled Wednesday with the essential quandary of the case: if the federal government can require Americans to buy medical insurance, what constitutional limit would prevent it from mandating all manner of purchases and activities?

10 Jun 2011

Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease

Interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott's investigational treatment for advanced Parkinson's disease showed that patients treated with levodopa-carbidopa intestinal gel (LCIG) for 12 weeks reported a decrease in "off" time and an increase in "on" time without troublesome dyskinesias.

9 Jun 2011

First Edition: June 9, 2011

Today's headlines include reports from yesterday's action in an Atlanta courtroom where oral arguments were held in an appeal related to the multi-state challenge to the health law.

9 Jun 2011

A big day for the multi-state challenge to the health law

Florida already leads a lawsuit challenging the federal health care law, but state officials are going a step further and ignoring the law almost entirely — rejecting millions of federal dollars to provide health care for retirees, seniors, children and people with disabilities.

9 Jun 2011

Drug that makes the failing heart heal itself

Researchers have found that a drug can heal heart muscles in mice. Earlier it was considered that this damage to the heart is permanent but this new findings refutes earlier beliefs.

9 Jun 2011

Therapeutic equivalent to replace penicillin

Antibiotics are among the greatest achievements of medical science. But lately the former multi-purpose weapon fails in the battle against infectious diseases. Bacteria are increasingly developing resistance to antibiotics. Researchers have now found a therapeutic equivalent which could replace penicillin and related phamaceuticals.

8 Jun 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011

Experts from The Cancer Institute, an NCI-designated cancer center, at NYU Langone Medical Center presented new research findings at the 47th American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago, IL.

8 Jun 2011

Pharmasset expands PSI-7977 clinical trial for treatment of chronic hepatitis C

Pharmasset, Inc. announced today the addition of three treatment cohorts to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV).

8 Jun 2011

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two studies of VELCADE (bortezomib) for Injection based combinations in patients with relapsed or refractory multiple myeloma (MM).

8 Jun 2011

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA.

8 Jun 2011

BPA affects development of uterus in female primates

Exposure in the womb to bisphenol A (BPA), a chemical widely used in the food and medical industries, causes changes in female primates' uterus development, new research suggests. The results will be presented Tuesday at The Endocrine Society's 93rd Annual Meeting in Boston.

8 Jun 2011

Oral News and Research

Cinryze data on hereditary angioedema presented at EAACI 2011

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Cypress receives FDA approval for ZUTRIPRO, REZIRA NDA to treat cough and common cold

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Merck receives FDA approval for redesigned drug container labels

First Edition: June 10, 2011

Battle over health law moves to Atlanta courtroom as judges weigh limits of the measure's powers

Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease

First Edition: June 9, 2011

A big day for the multi-state challenge to the health law

Drug that makes the failing heart heal itself

Therapeutic equivalent to replace penicillin

NYU Cancer Institute scientists present new research findings at ASCO 2011

Pharmasset expands PSI-7977 clinical trial for treatment of chronic hepatitis C

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

BPA affects development of uterus in female primates

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News